CD95 Maintains Stem Cell-like and Non-classical EMT Programs in Primary Human Glioblastoma Cells

Overview

Journal Cell Death Dis

Specialties Cell Biology
General Medicine

Date 2016 Apr 29

PMID 27124583

Citations 33

Authors

M Drachsler

S Kleber

A Mateos

K Volk

N Mohr

S Chen

B Cirovic

J Tuttenberg

C Gieffers

J Sykora

C R Wirtz

W Mueller

M Synowitz

A Martin-Villalba

Affiliations

Soon will be listed here.

Abstract

Glioblastoma (GBM) is one of the most aggressive types of cancer with limited therapeutic options and unfavorable prognosis. Stemness and non-classical epithelial-to-mesenchymal transition (ncEMT) features underlie the switch from normal to neoplastic states as well as resistance of tumor clones to current therapies. Therefore, identification of ligand/receptor systems maintaining this privileged state is needed to devise efficient cancer therapies. In this study, we show that the expression of CD95 associates with stemness and EMT features in GBM tumors and cells and serves as a prognostic biomarker. CD95 expression increases in tumors and with tumor relapse as compared with non-tumor tissue. Recruitment of the activating PI3K subunit, p85, to CD95 death domain is required for maintenance of EMT-related transcripts. A combination of the current GBM therapy, temozolomide, with a CD95 inhibitor dramatically abrogates tumor sphere formation. This study molecularly dissects the role of CD95 in GBM cells and contributes the rational for CD95 inhibition as a GBM therapy.

Citing Articles

Mesenchymal Properties of Glioma Cell Lines.

Kholodenko I, Lupatov A, Kim Y, Saryglar R, Kholodenko R, Yarygin K Bull Exp Biol Med. 2024; 178(1):122-129.

PMID: 39585593 DOI: 10.1007/s10517-024-06294-7.

Glioblastoma functional heterogeneity and enrichment of cancer stem cells with tumor recurrence.

Xie X, Ganbold M, Li J, Lien M, Chipman M, Wang T Neuron. 2024; 112(24):4017-4032.e6.

PMID: 39510072 PMC: 11659040. DOI: 10.1016/j.neuron.2024.10.012.

Prognostic Value of Fas/Fas Ligand Expression on Circulating Tumor Cells (CTCs) and Immune Cells in the Peripheral Blood of Patients with Metastatic Breast Cancer.

Papadaki M, Papadaki E, Chatziavraam S, Aggouraki D, Michaelidou K, Fotsitzoudis C Cancers (Basel). 2024; 16(17).

PMID: 39272785 PMC: 11393959. DOI: 10.3390/cancers16172927.

IRE1 RNase controls CD95-mediated cell death.

Pelizzari-Raymundo D, Maltret V, Nivet M, Pineau R, Papaioannou A, Zhou X EMBO Rep. 2024; 25(4):1792-1813.

PMID: 38383861 PMC: 11014915. DOI: 10.1038/s44319-024-00095-9.

A Novel Molecular Classification Method for Glioblastoma Based on Tumor Cell Differentiation Trajectories.

Zhang G, Xu X, Zhu L, Li S, Chen R, Lv N Stem Cells Int. 2023; 2023:2826815.

PMID: 37964983 PMC: 10643041. DOI: 10.1155/2023/2826815.

References

Kleber S, Sancho-Martinez I, Wiestler B, Beisel A, Gieffers C, Hill O . Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell. 2008; 13(3):235-48. DOI: 10.1016/j.ccr.2008.02.003. View

Fischer K, Durrans A, Lee S, Sheng J, Li F, Wong S . Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature. 2015; 527(7579):472-6. PMC: 4662610. DOI: 10.1038/nature15748. View

Creighton C, Li X, Landis M, Dixon J, Neumeister V, Sjolund A . Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A. 2009; 106(33):13820-5. PMC: 2720409. DOI: 10.1073/pnas.0905718106. View

Verhaak R, Hoadley K, Purdom E, Wang V, Qi Y, Wilkerson M . Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17(1):98-110. PMC: 2818769. DOI: 10.1016/j.ccr.2009.12.020. View

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View

Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S . A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008; 9(6):582-9. PMC: 2396950. DOI: 10.1038/embor.2008.74. View

. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008; 455(7216):1061-8. PMC: 2671642. DOI: 10.1038/nature07385. View

Son M, Woolard K, Nam D, Lee J, Fine H . SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell. 2009; 4(5):440-52. PMC: 7227614. DOI: 10.1016/j.stem.2009.03.003. View

Sun Y, Kong W, Falk A, Hu J, Zhou L, Pollard S . CD133 (Prominin) negative human neural stem cells are clonogenic and tripotent. PLoS One. 2009; 4(5):e5498. PMC: 2676510. DOI: 10.1371/journal.pone.0005498. View

10.

Corsini N, Sancho-Martinez I, Laudenklos S, Glagow D, Kumar S, Letellier E . The death receptor CD95 activates adult neural stem cells for working memory formation and brain repair. Cell Stem Cell. 2009; 5(2):178-90. DOI: 10.1016/j.stem.2009.05.004. View

11.

Barnhart B, Legembre P, Pietras E, Bubici C, Franzoso G, Peter M . CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. EMBO J. 2004; 23(15):3175-85. PMC: 514938. DOI: 10.1038/sj.emboj.7600325. View

12.

Trauth B, Klas C, Peters A, Matzku S, Moller P, Falk W . Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science. 1989; 245(4915):301-5. DOI: 10.1126/science.2787530. View

13.

Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M . The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell. 1991; 66(2):233-43. DOI: 10.1016/0092-8674(91)90614-5. View

14.

Singh S, Hawkins C, Clarke I, Squire J, Bayani J, Hide T . Identification of human brain tumour initiating cells. Nature. 2004; 432(7015):396-401. DOI: 10.1038/nature03128. View

15.

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

16.

Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner P . CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 2007; 67(9):4010-5. DOI: 10.1158/0008-5472.CAN-06-4180. View

17.

Wu Y, Zhou B . TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and invasion. Br J Cancer. 2010; 102(4):639-44. PMC: 2837572. DOI: 10.1038/sj.bjc.6605530. View

18.

Letellier E, Kumar S, Sancho-Martinez I, Krauth S, Funke-Kaiser A, Laudenklos S . CD95-ligand on peripheral myeloid cells activates Syk kinase to trigger their recruitment to the inflammatory site. Immunity. 2010; 32(2):240-52. DOI: 10.1016/j.immuni.2010.01.011. View

19.

Lathia J, Gallagher J, Heddleston J, Wang J, Eyler C, MacSwords J . Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell. 2010; 6(5):421-32. PMC: 2884275. DOI: 10.1016/j.stem.2010.02.018. View

20.

Chen L, Park S, Tumanov A, Hau A, Sawada K, Feig C . CD95 promotes tumour growth. Nature. 2010; 465(7297):492-6. PMC: 2879093. DOI: 10.1038/nature09075. View